The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Hospital, Baltimore, MD, USA.
Department of Pathology, Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Abdom Radiol (NY). 2024 Oct;49(10):3559-3573. doi: 10.1007/s00261-024-04358-w. Epub 2024 May 18.
Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer-related mortality and it is often diagnosed at advanced stages due to non-specific clinical presentation. Disease detection at localized disease stage followed by surgical resection remains the only potentially curative treatment. In this era of precision medicine, a multifaceted approach to early detection of PDAC includes targeted screening in high-risk populations, serum biomarkers and "liquid biopsies", and artificial intelligence augmented tumor detection from radiologic examinations. In this review, we will review these emerging techniques in the early detection of PDAC.
胰腺导管腺癌 (PDAC) 是癌症相关死亡的第三大主要原因，由于临床表现不具有特异性，通常在晚期诊断。局部疾病阶段的疾病检测后进行手术切除仍然是唯一潜在的治愈性治疗方法。在精准医学时代，PDAC 的早期检测包括高危人群的靶向筛查、血清生物标志物和“液体活检”，以及人工智能增强的影像学检查中的肿瘤检测。在这篇综述中，我们将回顾这些用于 PDAC 早期检测的新兴技术。
